Telix Pharmaceuticals is a radiopharmaceutical company focused on cancer imaging and therapies, with strong revenue growth driven by products like Illuccix and Gozellix. While recent gains suggest the stock may be stabilising, future performance will depend on continued commercial growth and pipeline progress.
Lynas Rare Earths is the largest rare earth producer outside China, supplying critical magnet materials used in EVs, renewable energy and defence technologies. Its core Mt Weld mine and expanding processing facilities position the company as a key player in the Western rare earth supply chain. While earnings remain highly sensitive to rare earth prices, ongoing capacity expansion and stronger NdPr demand could support significant long-term growth.
Mineral Resources is emerging from a heavy investment phase as the Onslow Iron project reaches scale, driving a sharp recovery in earnings and cash flow. With iron ore production ramped up and lithium assets backed by a major POSCO partnership, the business is now showing the financial benefits of years of expansion. Despite the turnaround, the stock still appears undervalued relative to its long‑term earnings, cash‑flow potential, and asset base.
TechnologyOne is a leading Australian SaaS provider delivering cloud ERP software to governments and large organisations. Its recurring revenue model supports strong margins and steady growth. However, the stock trades at a premium valuation, leaving little margin for growth disappointments.
Paladin Energy is a leveraged uranium producer centred on the restarted Langer Heinrich mine in Namibia. Its earnings are highly sensitive to uranium prices, making the stock a direct play on the nuclear fuel cycle. Future growth could come from the large Patterson Lake South project in Canada.
Immutep is a Sydney-based clinical-stage biotechnology company focused on immunotherapy, specifically targeting the LAG-3 immune pathway. The company is dual-listed on the ASX and NASDAQ, giving it access to both Australian and US capital markets. It does not yet generate commercial product revenue and remains dependent on capital markets and partnerships to fund its development programs, making it a milestone-driven investment rather than a revenue-backed operating business.
